糖尿病肾病患者接受普罗布考联合奥美沙坦酯治疗后糖脂代谢、氧化和炎症反应程度的评估  

Assessment of the glucolipid metabolism,oxidation and inflammation in patients with diabetic nephropathy after probucol combined with Olmesartan Medoxomil therapy

作　　者：李燕妮[1] 仲健[1] 郭秋野[1] 王晓雪[1] 

机构地区：[1]陕西省汉中市中心医院内分泌科,陕西汉中7223000

出　　处：《海南医学院学报》2016年第22期2699-2702,共4页Journal of Hainan Medical University

基　　金：陕西省社会发展攻关计划项目(2012SF2-26)~~

摘　　要：目的:分析糖尿病肾病患者接受普罗布考联合奥美沙坦酯治疗后糖脂代谢、氧化和炎症反应程度的变化。方法:108例糖尿病肾病患者随机分为观察组及对照组,各54例,对照组接受奥美沙坦酯治疗,观察组接受普罗布考联合奥美沙坦酯治疗,对比两组治疗后的血糖水平及波动程度、脂质代谢指标、氧化/抗氧化指标、炎症指标的差异。结果:观察组外周血空腹血糖(GLU)、平均血糖波动幅度(MAGE)、血糖水平标准差(SDBG)、平均餐后血糖波动幅度(MPPGE)水平均显著低于对照组(P<0.05);血清脂质指标总胆固醇(TC)、载脂蛋白B(ApoB)、低密度脂蛋白胆固醇(LDL-C)含量显著低于对照组(P<0.05),载脂蛋白A1(ApoA1)、载脂蛋白A5(ApoA5)、高密度脂蛋白胆固醇(HDL-C)含量显著高于对照组(P<0.05);血清氧化/抗氧化指标晚期蛋白氧化产物(AOPP)、丙二醛(MDA)、过氧亚硝基阴离子(ONOO﹣)含量显著低于对照组(P<0.05),总抗氧化能力(T-AOC)、超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-PX)含量显著高于对照组(P<0.05);血清炎症指标白介素-1β(IL-1β)、白介素-4(IL-4)、白介素-18(IL-18)、降钙素原(PCT)、转化生长因子(TGF)含量显著低于对照组(P<0.05)。结论:普罗布考联合奥美沙坦酯治疗可优化糖尿病肾病患者的整体病情,在均衡糖脂代谢、抑制氧化及炎症状态等方面均有积极作用。Objective： To analyze the changes of glucolipid metabolism, oxidation and inflammation in patients with dia- betic nephropathy after probucol combined with Olmesartan Medoxomil treatment. Methods.. A total of 108 patients with dia- betic nephropathy were randomly divided into observation group and control group （n = 54）, control group received Olmesartan Medoxomil therapy, and observation group received probucol combined with Olmesartan Medoxomil therapy. Differences in blood glucose and fluctuation levels, lipid metabolism indexes, oxidation/antioxidation indexes and inflammation indexes were compared between the two groups after treatment. Results.. GLU, MAGE, SDBG and MPPGE levels in peripheral blood of ob- servation group were significantly lower than those of control group~ lipid indexes TC, ApoB and LDL-C content in serum were significantly lower than those of control group while ApoA1, ApoA5 and HDL-C content were significantly higher than those of control group; oxidation/antioxidation indexes AOPP, MDA and ONOO - content in serum were significantly lower than those of control group while T-AOC, SOD and GSH-PX content were significantly higher than those of control group; inflam- mation indexes IL-1β, IL-4, IL-18, PCT and TGF content in serum were significantly lower than those of control group. Con- clusions： Probucol combined with Olmesartan Medoxomil therapy can optimize the overall condition in patients with diabetic nephropathy, and plays a positive role in equalizing glucolipid metabolism, inhibiting oxidation and inflammation state and oth-er aspects.

关 键 词：糖尿病肾病 普罗布考 奥美沙坦酯 糖脂代谢 

分 类 号：R587.2[医药卫生—内分泌]